scholarly journals Tu1837 – Developing a Novel Medication Adherence Index to Determine Reasons for Nonadherence in Inflammatory Bowel Disease

2019 ◽  
Vol 156 (6) ◽  
pp. S-1143-S-1144
Author(s):  
Aria Zand ◽  
Audrey Nguyen ◽  
Zack Stokes ◽  
Courtney Reynolds ◽  
Jenny Sauk ◽  
...  
2019 ◽  
Vol 13 (Supplement_1) ◽  
pp. S234-S234
Author(s):  
A Zand ◽  
A Nguyen ◽  
Z Stokes ◽  
C Reynolds ◽  
M Dimitrova ◽  
...  

2016 ◽  
Vol 150 (4) ◽  
pp. S556
Author(s):  
Mirjam Severs ◽  
Marie-Josée J. Mangen ◽  
Herma H. Fidder ◽  
Mirthe E. Van Der Valk ◽  
Mike Van Der Have ◽  
...  

2017 ◽  
Vol 152 (5) ◽  
pp. S123
Author(s):  
Philip Oppong Twene ◽  
Francis Farraye ◽  
Tanvi A. Dhere ◽  
Cameron B. Body ◽  
Rachel Patzer ◽  
...  

2019 ◽  
Vol 31 (8) ◽  
pp. 948-953 ◽  
Author(s):  
Ignacio Bruna-Barranco ◽  
Alberto Lué ◽  
Carla J. Gargallo-Puyuelo ◽  
María T. Arroyo ◽  
Erika Alfambra ◽  
...  

2016 ◽  
Vol 22 (9) ◽  
pp. 2158-2164 ◽  
Author(s):  
Mirjam Severs ◽  
Peter N. P. A. Zuithoff ◽  
Marie-Josée J. Mangen ◽  
Mirthe E. van der Valk ◽  
Peter D. Siersema ◽  
...  

2020 ◽  
Vol 2 (2) ◽  
Author(s):  
Melissa J Benson ◽  
Sarah V Abelev ◽  
Susan J Connor ◽  
Crispin J Corte ◽  
Lewis J Martin ◽  
...  

Abstract Background Medicinal cannabis (MC) is an increasingly utilized treatment option for various refractory diseases. While robust clinical evidence supporting MC efficacy in inflammatory bowel disease (IBD) is lacking, many IBD patients report using MC to obtain symptomatic relief. Understanding this use and associated outcomes may help inform future clinical trials. Methods A cross-sectional anonymous online survey was conducted involving Australians with IBD. It examined attitudes and experiences with MC in relation to IBD management. The survey included validated sub-questionnaires assessing quality of life, medication adherence, IBD severity, and functional impairment. Results A total of 838 responses were obtained. Results showed 25.3% (n = 212) of respondents were current or previous users of MC (18.1% current, 7.2% previous). Half of the current users also consumed cannabis recreationally although less frequently than for medicinal purposes. Cannabis consumption was via smoking (joints 34.2%; water pipe/bongs 14.5%) or as an oral liquid (19.7%) with products obtained from recreational dealers (44.6%), friends/family (26.1%), or self-grown (9.8%). Only 3 respondents reported using legally accessed products. Clinical ratings of IBD severity did not differ according to cannabis use although users reported more hospitalizations, less engagement with specialist services, and lower medication adherence. IBD symptoms reported as positively affected by cannabis included abdominal pain, stress, sleep, cramping, and anxiety. Most users (92.7%) endorsed cannabis as effective in symptom management. Cannabis-using ulcerative colitis patients reported better quality of life than nonusers on some measures. Conclusion Many patients in Australia are using illicit MC to manage their IBD. Further clinical trials are required to validate, or refute, patient claims around MC efficacy for symptom control in IBD.


Sign in / Sign up

Export Citation Format

Share Document